Patented technology for the production of full-length, correctly folded and functional proteins
Identify all autoantigens and antigens that make up the Autoproteome*
(*) Totality of all possible autoantigens and neoantigens representing a given disease and its sub-types
The Sengenics AxCESS research service packages feature three KREX-based functional protein arrays developed for high-throughput and cost-effective immuno-proteomics applications. These protein arrays utilise the patented KREX protein folding technology for the production of full-length, correctly folded and functional proteins.
This range of arrays provide easy access to Sengenics’ KREX technology to enable high-specificity autoantibody characterisation with a focus on autoimmune, cancer and neurodegenerative disorders. All packages are carried out on a standard “fee-for-service” basis that include running of assays with integrated bioinformatics analysis and reporting.
Sengenics Immunome AxCESS Array
Contains over 1600 correctly folded and functional human proteins spotted in duplicate. Screen up to 2 samples per slide. Key applications include:
Sengenics CTA AxCESS Array
Contains over 200 correctly folded and functional CT antigens spotted in duplicate. Screen up to 8 samples per slide. Key applications include:
Sengenics OncoREX p53 Array
Contains over 100 correctly folded and functional wild type and mutant p53 spotted in duplicate. Screen up to 8 samples per slide. Key applications include:
Sengenics ImmuSAFE COVID+ Array
Measure three critical components of COVID-19 from a single sample on one chip:
Contains multiple SARS-CoV-2 specific domains (Nucleocapsid and Spike proteins) including full-length and numerous truncated versions and IFN, TNF, ANA etc. Key applications include:
Sengenics is actively seeking collaborators for joint research and development programs in specific, market-addressable, cancer and autoimmune diseases. We also have a keen interest in Alzheimer’s and Parkinson’s research. Under our Discovery program, Sengenics offers its products and services under a collaborative framework encompassing sharing of IP and commercialisation rights.
We are also interested to hear from pharmaceutical, biopharmaceutical and biotech companies with an interest to discover, develop or license in diagnostic, drug response prediction or ADR/irAE prediction biomarker signatures.
Sengenics KREX Custom Array
SEROMAX Blood Collection Kit
SYMPHONI
High-throughput autoantibody profiling against 1600+ proteins
Quantification of autoantibodies to 200+ clinically relevant CT antigens
Simultaneous screening of 100+
wild-type and mutant p53
Multi-antigen, multi-domain
COVID-19 antibody test
